UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...

89bio, Inc. has announced the launch of an underwritten public offering for $250 million in common stock, with the option for some investors to purchase pre-funded warrants instead. The company ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.